News | Heart Failure | March 04, 2023

New Analyses of Sotagliflozin Showing Time to Clinical Benefit Presented at ACC23

Statistically significant reduction in the risk for the primary outcome on Day 27

Statistically significant reduction in the risk for the primary outcome on Day 27

March 4, 2023 - Lexicon Pharmaceuticals, Inc.  announced new analyses of results from the SOLOIST-WHF Phase 3 outcomes study of its investigational product sotagliflozin presented at the American College of Cardiology’s 72nd Annual Scientific Session Together With World Heart Federation’s World Congress of Cardiology in New Orleans, Louisiana.

The “Time to Clinical Benefit of Sotagliflozin in People with Worsening Heart Failure in SOLOIST-WHF” post hoc analysis examined the timing of clinical benefit of sotagliflozin, defined as the first day post randomization when the hazard ratio (HR) for risk for the primary outcome of total number of cardiovascular deaths, hospitalizations for heart failure, and urgent visits for heart failure was statistically significant (p<0.05) and remained significant throughout follow up. A subgroup analysis was also conducted in patients with left ventricular ejection fraction (LVEF) < 50% or ≥ 50%.

The analysis showed a statistically significant reduction in the risk for the primary outcome on Day 27, or time to clinical benefit of 27 days, in patients with worsening heart failure (WHF) treated with sotagliflozin. Furthermore, these findings were generally consistent across the LVEF range.

“Patients with heart failure admitted with worsening disease are at substantial risk for rehospitalization and death in the short-term,” stated Dr. Deepak L. Bhatt, Director of Mount Sinai Heart and the Dr. Valentin Fuster Professor of Cardiovascular Medicine at Icahn School of Medicine at Mount Sinai. “In SOLOIST-WHF, early initiation of sotagliflozin reduced the risk of cardiovascular events in the short-term and also in the long-term.”

As previously reported, in patients admitted with WHF, sotagliflozin significantly reduced the composite of total cardiovascular (CV) death, hospitalization for heart failure (HHF), and urgent visit for heart failure (UVHF) by 33%.

For more information: www.lexpharma.com

Find more ACC23 conference coverage here


Related Content

News | ACC

March 21, 2023 — As part of its extensive coverage, the editorial team at dicardiology.com/DAIC has shared summary ...

Home March 21, 2023
Home
News | ACC

March 16, 2023 — The American College of Cardiology (ACC) announced the winners and finalists of its 2023 Young ...

Home March 16, 2023
Home
News | ACC

March 12, 2023 — As part of its ongoing news coverage of ACC23, the DAIC/dicardiology.com editorial team has condensed ...

Home March 12, 2023
Home
News | ACC

March 9, 2023 — C. Noel Bairey Merz, MD, FACC, professor of cardiology and the director of the Barbra Streisand Women’s ...

Home March 09, 2023
Home
News | ACC

March 9, 2023 — Positive results from a Mineralys Therapeutics study, the Target-HTN Phase 2 trial, demonstrated ...

Home March 09, 2023
Home
News | ACC

March 8, 2023 — B. Hadley Wilson, MD, FACC, is the new president of the American College of Cardiology. Today marks the ...

Home March 08, 2023
Home
News | ACC

March 6, 2023 — In findings presented from the STELLAR Phase III Trial during the American College of Cardiology’s 2023 ...

Home March 06, 2023
Home
News | ACC

March 7, 2023 — A virtual care team-guided strategy for guideline-directed medical therapy (GDMT) optimization was found ...

Home March 06, 2023
Home
News | ACC

March 5, 2023 — Making a connection between the flu and the risk of subsequent heart problems significantly increased ...

Home March 05, 2023
Home
Feature | ACC | Christine Book

March 4, 2023 — Of the immense volume of valuable information offered and exchanged during the first day of the American ...

Home March 04, 2023
Home
Subscribe Now